Search results
Showing 61 to 71 of 71 results for psoriasis
Lay representatives David Chandler David is chief executive of the Psoriasis and Psoriatic Arthritis Alliance (PAPAA), a UK patient...
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
In development [GID-TA11189] Expected publication date: TBC
Apremilast for treating moderate to severe plaque psoriasis (TA368)
This guidance has been updated and replaced by NICE technology appraisal guidance 419. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further...
NICE approves first treatment in pilot of new approach to cost-comparison fast track appraisals
As part of the recovery from the COVID-19 pandemic, NICE has been working hard to find new ways to develop and publish guidance affected by the work programme pause in 2020, while also delivering the planned programme for 2021.